Literature DB >> 29033821

Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis.

Hiroyuki Sakai1, Wakana Nomura1, Motoshi Sugawara1.   

Abstract

Anti-tumor necrosis factor α (TNF-α) biologic agents are used for treating refractory sarcoidosis. However, sarcoidosis-like epithelioid cell granulomas may develop during anti-TNF-α treatment. A 63-year-old man suffering from rheumatoid arthritis was treated with oral methotrexate and methylprednisolone for 4 years. He subsequently started biweekly subcutaneous injections of certolizumab pegol. Three months later, light red follicular papules developed on his chest and they spread over the trunk and bilateral upper arms. Histopathology of a lesion showed a sharply demarcated noncaseating epithelioid cell granuloma with multi-nucleated giant cells in the upper perifollicular area. The follicular papules subsided following discontinuation of certolizumab pegol. Folliculitis-like lichenoid sarcoidosis should be included among the adverse cutaneous reactions of anti-TNF-α treatment.

Entities:  

Keywords:  Anti-TNF-α; Certolizumab pegol; Lichenoid sarcoidosis; Paradoxical reaction; Rheumatoid arthritis

Year:  2017        PMID: 29033821      PMCID: PMC5636996          DOI: 10.1159/000477957

Source DB:  PubMed          Journal:  Case Rep Dermatol        ISSN: 1662-6567


Introduction

Anti-tumor necrosis factor α (TNF-α) therapy is effective for several immune-mediated inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel diseases, psoriasis, and sarcoidosis. However, anti-TNF-α agents may also paradoxically induce or exacerbate these inflammatory diseases. Herein, we present a case of paradoxical lichenoid sarcoidosis in a patient with rheumatoid arthritis who was treated with certolizumab pegol (CZP).

Case Report

A 63-year-old man had been suffering from rheumatoid arthritis for 4 years. He received oral methotrexate and methylprednisolone without satisfactory therapeutic response. Biweekly subcutaneous injection of CZP was added in September 2013. Three months later, he visited our clinic due to pruritic reddish eruptions on his chest. A physical examination revealed light red follicular papules that were approximately 2 mm in size on his chest. Topical and oral antibiotic therapies were not effective, and the skin lesions gradually spread over the trunk and bilateral upper arms (Fig. 1a, b). A skin biopsy of a papule disclosed a sharply demarcated non-caseating epithelioid cell granuloma with multi-nucleated giant cells in the upper perifollicular area. Considerable mononuclear lymphoid cells had infiltrated around the granuloma (Fig. 2). Neither Ziehl-Neelsen staining nor auramine staining identified any acid-fast bacilli. A blood test, chest roentgenographic examination, and computed tomography did not reveal any remarkable change. An ophthalmological examination did not reveal any signs of ocular sarcoidosis or tuberculosis (TB). The patient's serum angiotensin-converting enzyme level was normal. The tuberculin skin test and interferon-gamma release test (QuantiFERON® TB-Gold) results were marginally positive (10 × 10 mm and 0.10 IU/mL, respectively). These findings suggested the diagnosis of lichen scrofulosorum. We discontinued CZP and started anti-TB therapy. The follicular papules began to subside. However, at 8 weeks following the initiation of anti-TB therapy, exudative erythema developed with histopathological findings of epidermal spongiosis and massive dermal eosinophilic infiltration. A drug-induced lymphocyte stimulation test for rifampicin was positive and the anti-TB therapy was discontinued. During the course of these events, the patient's rheumatoid arthritis worsened with marked arthralgia, which urged us to re-initiate the CZP therapy. Several follicular papules reappeared again, but they improved with topical glucocorticoid therapy. Eight weeks after starting the second CZP treatment, the patient developed arrhythmia and CZP was discontinued. The follicular papules gradually subsided and did not develop again. We finally diagnosed the skin lesions as lichenoid sarcoidosis.
Fig. 1

Light red follicular papules of approximately 2 mm in size are distributed on the chest (a) and right upper arm (b).

Fig. 2

A skin biopsy specimen taken from the patient's abdomen shows a sharply demarcated non-caseating epithelioid cell granuloma with multi-nucleated giant cells in the upper perifollicular area.

Discussion

The patient's follicular papules were initially suspected to be superficial bacterial folliculitis. However, histopathology of the lesion disclosed a non-caseating epithelioid cell granuloma in the upper dermal perifollicular area, suggesting the diagnosis of lichen scrofulosorum. This was excluded because: (1) the patient did not develop TB during the oral methotrexate and methylprednisolone therapy, suggesting that he did not have latent TB; (2) TB bacilli were never detected in the skin lesions; (3) no obvious systemic TB developed after the re-initiation of CZP therapy; (4) after cessation of the CZP therapy, the follicular papules subsided without anti-TB drugs; and (5) the follicular papules responded to topical glucocorticoid treatment. These findings together with the histopathology led to the diagnosis of CZP-induced lichenoid sarcoidosis. Sarcoidosis is a multi-organ chronic inflammatory disease characterized by non-caseating epithelioid cell granulomas. TNF-α is among the key cytokines of granuloma formation, and anti-TNF-α treatment has been shown to be effective for refractory sarcoidosis [1, 2]. More than 50 cases of anti-TNF-α therapy-associated sarcoidosis have been reported [1]. In approximately 75% of the cases, the clinical presentation was systemic, mainly respiratory symptoms, such as dyspnea, chest pain, and cough. So far, 17 cases, including ours, of cutaneous non-caseating “sarcoidosis-like” granulomas with or without visceral involvement have been described (Table 1). The cutaneous manifestations include papules, nodules, plaques, subcutaneous masses, scar infiltration, and follicular papules (the current case). The time lapse between the initiation of anti-TNF-α treatment and the onset of sarcoidosis varies from 1 month to 4 years. However, in approximately half of the cases (9/17), granulomas developed within the first year of treatment.
Table 1

Cases of cutaneous sarcoidosis during anti-TNF-αtreatment

First author [Ref.]Anti-TNF-α agentAge, years/sexUnderlying diseaseTime interval between treatment and onsetClinical manifestations of the cutaneous granulomatous lesionsOther organ involvement
Peno-Green [3]ETA50/FRA2 monthsScattered nonpruritic skin lesions on the plantar surfaces of both feet and at the site of superficial scars on the extremitiesDiffuse reticulonodular infiltrates in the mid- and lower lung zones

González-López [4]ETA70/MAS19 monthsFirm, nontender, red-brown nodular lesions on the faceBilateral hilar and paratracheal lymphadenopathy

Bachmeyer [5]ETA39/MAS1 monthAsymptomatic erythematous papules on a tattooNo

Verschueren [6]ETA46/FRA12 monthsA plaque lesion on the right forearmBilateral hilar and paratracheal lymphadenopathy

Daïen [7]ETA46/MPsA2 monthsThree cutaneous nodules on the faceNo

ETA72/FRA18 monthsInflammatory and painful scarsNo

IFX54/FAS14 monthsBrownish nodules on arms and legsBasal infiltration and mediastinal lymph node

ADA53/FRA21 monthsNodules on lower limbsMediastinal lymph nodes and infiltrates

Dhaille [8]IFX47/MPsA4 monthsPainful subcutaneous firm nodules on the right temple, palms, soles, knees, sternal area, and scarsNo

ADA56/FPJR1 monthsRed nodular lesions on the right forearm, ankles, and legs with increased redness of pre-existing scarsNo

Takahashi [9]IFX35/MCD7 monthsAn infiltrated erythematous plaque on the right kneeBilateral nodular infiltrates and miliary reticulonodular densities of the lung

Clementine [10]IFX49/FRA60 monthsMultiple shiny violaceous erythematous papules on the left lower legAnterior uveitis, hilar and mediastinal lymphadenopathy, fibrotic lung disease

Burns [11]ETA59/FRA48 monthsA subcutaneous mass measuring 4×7 cm on the left forearm and multiple smaller nodules on the distal upper extremities, knees, and buttocksPretracheal, subcranial, hilar and peribronchial adenopathy

Fok [12]IFX66/FUC23 monthsIncreased prominence of previous scars and several painful dermal nodules over the extensor surfaces of the upper and lower limbsNo

Lamrock [13]ETA56/FPsA9 monthsErythematous nodules on the knees and right elbowNo

Au [14]ADA49/FSarcoidosis8 monthsMultiple subcutaneous nodules on the arms and legsPulmonary sarcoidosis, costochondritis secondary to sarcoidosis

Present caseCZP63/MRA3 monthsDisseminated follicular papules on the trunk and armsNo

AS, ankylosing spondylitis; CD, Crohn disease; PJR, polyarticular juvenile rheumatoid arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis; ADA, adalimumab; CZP, certolizumab pegol; ETA, etanercept; IFX, infliximab.

In conclusion, we present the first case of rheumatoid arthritis with lichenoid sarcoidosis induced by the anti-TNF-α agent CPZ. The patient's skin lesions mimicked superficial folliculitis, which is relatively common in cases under immunosuppressive treatments. Folliculitis-like lichenoid sarcoidosis should also be considered in patients receiving anti-TNF-α treatment as adverse cutaneous reactions, especially when follicular papules do not respond to conventional anti-microbial treatment.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

The authors declare no conflicts of interest.
  14 in total

1.  Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.

Authors:  Sonoa Au; Mehdi Mirsaeidi; Iris K Aronson; Nadera J Sweiss
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-10-20       Impact factor: 0.670

2.  Sarcoidosis during infliximab therapy for Crohn's disease.

Authors:  Hidetoshi Takahashi; Kazuhiro Kaneta; Masaru Honma; Akemi Ishida-Yamamoto; Tomonori Ashida; Yutaka Kohgo; Yoshinobu Ohsaki; Hajime Iizuka
Journal:  J Dermatol       Date:  2010-05       Impact factor: 4.005

3.  Granulomatous tattoo reaction in a patient treated with etanercept.

Authors:  C Bachmeyer; L Blum; B Petitjean; F Kemiche; E Pertuiset
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-04       Impact factor: 6.166

Review 4.  Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.

Authors:  Kum C Fok; Watson W S Ng; Christopher J A Henderson; Susan J Connor
Journal:  J Crohns Colitis       Date:  2012-01-29       Impact factor: 9.071

Review 5.  Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.

Authors:  F Dhaille; V Viseux; A Caudron; A Dadban; C Tribout; P Boumier; A Clabaut; C Lok
Journal:  Dermatology       Date:  2010-02-20       Impact factor: 5.366

6.  Lung injury linked to etanercept therapy.

Authors:  Laura Peno-Green; Geronomo Lluberas; Thomas Kingsley; Steven Brantley
Journal:  Chest       Date:  2002-11       Impact factor: 9.410

Review 7.  Treatment of Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

8.  Tumor necrosis factor-alpha antagonist-induced sarcoidosis.

Authors:  Rochelle Robicheaux Clementine; Justin Lyman; Jerald Zakem; Jyothi Mallepalli; Stephen Lindsey; Robert Quinet
Journal:  J Clin Rheumatol       Date:  2010-09       Impact factor: 3.517

9.  Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab.

Authors:  Ariel M Burns; Peter J Green; Sylvia Pasternak
Journal:  J Cutan Pathol       Date:  2011-09-07       Impact factor: 1.587

Review 10.  Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.

Authors:  Edwina Lamrock; Pam Brown
Journal:  Australas J Dermatol       Date:  2012-02-16       Impact factor: 2.875

View more
  2 in total

1.  Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review.

Authors:  Anna Gawdzik; Małgorzata Ponikowska; Alina Jankowska-Konsur; Zdzisław Woźniak; Joanna Maj; Jacek C Szepietowski
Journal:  Dermatol Ther (Heidelb)       Date:  2020-05-23

2.  Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.

Authors:  Keigo Koda; Mikio Toyoshima; Tsuyoshi Nozue; Takafumi Suda
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.